Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Emerging Molecular Targets For Advanced Non-Small Cell Lung Cancer (NSCLC)
Video Library
Search the Video Library
Video Language
Filter by Cancer Type:
Displaying Results 1 - 15 of 108
Lung Cancer Video Library
Dr. Jared Weiss, UNC Lineberger Comprehensive Cancer Center, discusses the genetic risk (or lack thereof) for lung cancer.
Please Note: New Treatments Have Emerged Since this Original Post
Dr. Nathan Pennell, Cleveland Clinic, reviews the available trial evidence for the use of targeted therapies in the post-operative/adjuvant setting.
Dr. Jack West, medical oncologist/lung cancer specialist, describes special management considerations for indolent lung cancers that may not require treatment or are at risk for “over-treatment.”
Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.
Dr. David Harpole, Duke University Medical Center, details the methods thoracic surgeons use to assess a patient's fitness for surgery.
Dr. David Harpole, Duke University Medical Center, describes the mediastinoscopy and its use in lung cancer staging.
Transcript Historically, lung cancer has been treated with a large incision between the ribs, and in the early-mid ‘90s we began to investigate uses of the laparoscope, which was used to do gallbladders and so forth, in the chest. So we began using the devices to do more limited resections with this
Dr. Heather Wakelee, Stanford University Medical Center, lists standard adjuvant chemotherapy regimens, comparing their administration and uses.
Dr. Heather Wakelee, Stanford University Medical Center, evaluates the lack of evidence for the use of targeted therapies after surgery, and describes ongoing trials attempting to resolve that issue.
Transcript More and more, when people are doing molecular testing on their tumor, they’re not just getting one test and if it’s negative doing another test — that’s called sequential testing, they’re doing lots of tests at the same time — that’s called multiplex testing. There are certain good
Dr. Ross Camidge, University of Colorado, describes ALK rearrangements and the characteristics of patients who most often have them.
Dr. Ross Camidge, University of Colorado, describes ROS-1 rearrangements and compares them to ALK rearrangements in frequency of occurrence and response to treatment.
Dr. Jed Gorden, Swedish Cancer Institute, describes the differences between bronchoscopy and endobronchial ultrasound, highlighting the advantages of EBUS in diagnosis and staging.
Dr. Ed Kim from the Levine Cancer Institute in Charlotte, NC summarizes the mechanism of next generation sequencing (NGS), how it can potentially be used, and its limitations in clinical practice today.